Atorvastatin + Simvastatin + Rozuvastatin + Ezetimibe + Niacin + Ciprofibrate + Fenofibrate + Bezafibrate + Evolocumab + Alirocumab + Inclisiran
Pre-clinicalRecruiting 0 watching 0 views this week💤 Quiet
23
Development Stage
1
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Atherosclerotic Cardiovascular Disease
Conditions
Atherosclerotic Cardiovascular Disease
Trial Timeline
Apr 15, 2025 → Sep 30, 2027
NCT ID
NCT06858332About Atorvastatin + Simvastatin + Rozuvastatin + Ezetimibe + Niacin + Ciprofibrate + Fenofibrate + Bezafibrate + Evolocumab + Alirocumab + Inclisiran
Atorvastatin + Simvastatin + Rozuvastatin + Ezetimibe + Niacin + Ciprofibrate + Fenofibrate + Bezafibrate + Evolocumab + Alirocumab + Inclisiran is a pre-clinical stage product being developed by Novartis for Atherosclerotic Cardiovascular Disease. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06858332. Target conditions include Atherosclerotic Cardiovascular Disease.
Hype Score Breakdown
Clinical
5
Activity
2
Company
10
Novelty
2
Community
1
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06858332 | Pre-clinical | Recruiting |
Competing Products
20 competing products in Atherosclerotic Cardiovascular Disease
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Rosuvamibe + Monorova | Yuhan | Approved | 85 |
| Rosuvamibe + Monorova | Yuhan | Approved | 85 |
| Lepodisiran Sodium + Placebo | Eli Lilly | Phase 3 | 77 |
| Retatrutide + Placebo | Eli Lilly | Phase 3 | 77 |
| Placebo + AZD0780 | AstraZeneca | Phase 2 | 52 |
| Clopidogrel + Ticagrelor | AstraZeneca | Approved | 85 |
| Epanova® (omega-3 carboxylic acids) + corn oil control | AstraZeneca | Phase 3 | 77 |
| atorvastatin + placebo | Merck | Phase 1 | 33 |
| Anacetrapib + Placebo anacetrapib | Merck | Phase 3 | 77 |
| Ranolazine 500 mg | Novartis | Phase 2 | 52 |
| Inclisiran + Background lipid lowering therapy | Novartis | Phase 3 | 77 |
| Inclisiran + Evolocumab | Novartis | Phase 2 | 52 |
| Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL + Placebo in 1.5ml | Novartis | Phase 3 | 77 |
| atorvastatin + inclisiran | Novartis | Approved | 85 |
| TQJ230 + Placebo | Novartis | Phase 3 | 77 |
| Inclisiran + Placebo | Novartis | Phase 3 | 77 |
| Pelacarsen | Novartis | Pre-clinical | 23 |
| Inclisiran | Novartis | Phase 3 | 77 |
| Inclisiran | Novartis | Approved | 85 |
| Pelacarsen (TQJ230) | Novartis | Phase 3 | 77 |